Tag:
Endo Pharmaceuticals
Latest Headlines
Latest Headlines
BDSI snags $2.5M milestone from Meda
BioDelivery Sciences International is in line for $2.5 million milestone payment from Meda, as Breakyl got its first regulatory clearance in the E.U.
Mersana snaps up $270M cancer drug deal with Endo Pharma
Endo Pharmaceuticals ( $ENDP ) has tapped Mersana to create antibody-drug conjugates against an undisclosed cancer target.
GSK pulls blood pressure pills made at Novartis plant
GlaxoSmithKline ( $GSK ) is the latest company to have to pull off the market a drug manufactured at Novartis' ( $NVS ) deeply troubled plant in Lincoln, NE. GSK recalled nearly 400,000 bottles of...
Novartis says Nebraska plant to reopen midyear
The Novartis ( $NVS ) Nebraska plant closed in December because a host of over-the-counter products contained stray pieces from other drugs is expected to reopen this summer. Twice in recent days...
Endo grabs BDSI's drug film chronic pain treatment through global license
BioDelivery Sciences International ( $BDSI )'s dissolvable drug delivery film to treat chronic pain from inside the cheek is still under development and endured a recent clinical setback. But it's
BioDelivery Sciences shares spike on $180M pain drug deal with Endo Pharma
BioDelivery Sciences International ( $BDSI ) surged out of penny-stock territory this morning on news of its deal with Endo Pharmaceuticals ( $ENDP ) to partner on a version of the painkiller
Purdue, Endo answer calls to deal with painkiller abuse
Officials from Kentucky and Florida want the makers of addictive painkillers to "take responsibility," because their current efforts at cooperating with law enforcement and educating consumers and
Panel mulls tougher rules for transvaginal meshes
Makers of vaginally implanted surgical meshes, including Johnson & Johnson ( $JNJ ), Endo Pharmaceuticals Holdings and C.R. Bard, could eventually be required to initiate studies on their products
Endo shutters a pain program following trial failure
There will be no third act for Endo's pain drug partnership with Grunenthal. Endo had originally signed on to the pact in early 2009, gaining U.S. marketing rights to axomadol. But earlier this
Endo pain drug flunks a Ph2 test
A little more than two years after in-licensing a pain drug from Grunenthal, Endo Pharmaceuticals said today that the treatment failed a mid-stage, placebo-controlled study for lower back pain. Endo
